Merck & Co's LDL-lowering drug Vytorin meets study endpoints

18 November 2014
merck-700

Pharma giant Merck & Co (NYSE: MRK) has announced that the study investigating LDL-cholesterol-lowering drug Vytorin (ezetimibe/simvastatin) – which combines simvastatin with the non-statin Zetia (ezetimibe) – has met its primary and secondary endpoints.

In the 18,144-patient IMPROVE-IT study, patients taking Vytorin experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone.

IMPROVE-IT was designed to address whether lowering LDL-cholesterol to well under 70mg/dL by adding ezetimibe to a statin further reduced cardiovascular events. This is because high-risk patients treated with statins, including those on treatment with low levels of LDL-cholesterol, continue to be at increased cardiovascular risk.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >




Company Spotlight